Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3, Multicenter, Open-label, Randomized Study to Evaluate the Efficacy and Safety of Fedratinib Compared to Best Available Therapy (BAT) in Subjects With DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) and Previously Treated With Ruxolitinib
Eligible participants will undergo 2:1 randomisation to fedratinib or best available therapy (BAT). Participants randomised to receive fedratinib will self-administer 400mg of the investigational product on an outpatient basis, once daily, preferably with food during an evening meal at the same time each day for consecutive 4-week cycles. Best available therapy will be selected by the investigator.